Nanoerythrocytes in Cancer Therapy Advancing Targeted Chemotherapy and Theranostics

Chapter 1. Overview of Erythrocytes and Nano Erythrocytes
Anuja Shashikant Kamble, Ashish Dilip Sutar, Rahul Shukla.

Chapter 2. Nanoerythrocytes as an Efficient Novel Drug Delivery System: From Concepts to Clinics
Dr. Vikas Maharshi, Dr. Sachin Kumar.

Chapter 3. Formulation Strategies for Erythrocytes as Drug Delivery Systems
Priya Gupta, Disha Marwaha, Shwetakshi Sharma.

Chapter 4. Promising Pathways in the Field of Cancer
Pankaj Kumar, Pankaj Musyuni.

Chapter 5. Theranostic Application of Nanoerythrocytes in Cancer
Shwetakshi Sharma, Pallavi Barik, Priya Gupta.

Chapter 6. Recent Patents of Nano Erythrocytes in Cancer
Archana Kumari, Pranjal Kumar, Ghanshyam Das Gupta, Kalicharan Sharma.

Chapter 7. Recent Clinical Trials of Nanoerythrocytes in Cancer
Avinash Kumar Singh, Arya Vidyadhari.

Chapter 8. Ethical and Regulatory Considerations of Cell-Based Therapies
Tanya Ralli, Abdul Salam Ahalami, Ram Sharma.

Chapter 9. Immunogenicity of Cell-Based Therapy
Avinash Kumar Singh, Arya Vidyadhari.

Biography

Dr. Bharti Mangla is working as an Assistant Professor in the Institute of Pharmaceutical Research (IPR), GLA University, Mathura 281406 UP, India. Formerly served as an Assistant Professor in the Department of Pharmaceutics at Delhi Pharmaceutical Sciences and Research University (DPSRU), New Delhi. She also held the role of Chief Operating Officer (COO) at the DPSRU Innovation and Incubation Foundation. With a doctorate in Pharmaceutics from Jamia Hamdard, New Delhi, Dr. Mangla has a distinguished academic background, having received gold medals at both the undergraduate (B. Pharmacy) and postgraduate (M. Pharmacy in Pharmaceutics) levels from Pandit Bhagwat Dayal Sharma University of Health Sciences, Rohtak.  With over eight years of academic and research experience, Dr. Mangla has made significant contributions to formulation development, particularly for diseases such as skin cancer, breast cancer, arthritis, wound healing, and diabetes. She has successfully developed various nanoformulations using different anticancer drugs, specifically targeting skin and breast cancer. Dr. Mangla has filed three patents, authored two international books, contributed five book chapters, and published over 35 international papers in peer-reviewed journals. Dr. Mangla has been honored with several national awards, including recognition for publishing in high-impact journals and for her outstanding performance in poster and oral presentations at conferences. 

Prof. Kanchan Kohli is a distinguished academician with a B.Pharmacy and M.Pharmacy from Delhi University and a Ph.D. in Pharmaceutics from Jamia Hamdard. Currently serving as an Adjunct Professor at Gurugram University, Dr. Kohli brings 37 years of combined teaching and research experience, having held positions such as Lecturer, Reader, Senior Lecturer, Professor, and Deputy Director at the All-India Council for Technical Education (AICTE). Dr. Kohli has also served as Director of Research & Publication and was a former Professor at the Department of Pharmaceutics, Jamia Hamdard. Throughout their career, Dr. Kohli has guided 40 Ph.D. and M. Pharm students and has published 270 papers in peer-reviewed journals. Her consultancy work with prominent industries such as Alkem, Patanjali, Cadila Pharmaceuticals, and Amway, along with a submitted BIRAC project in collaboration with the Bio-NEST NIPER-Guwahati Incubation Centre, underscores her contribution to applied research. She has received several prestigious awards, including the UGC Research Award in 2002 and the IPA-ACG SCITECH Innovation Award in 2017. In addition, Dr. Kohli holds 20 international and Indian patents.